Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

4159 - Impact of nutritional derangement on treatment outcome in advanced non-small-cell lung cancer (A-NSCLC) patients (pts).


28 Sep 2019


Poster Display session 1


Supportive Care and Symptom Management

Tumour Site

Non-Small Cell Lung Cancer


Ilaria Trestini


Annals of Oncology (2019) 30 (suppl_5): v718-v746. 10.1093/annonc/mdz265


I. Trestini1, I. Sperduti2, M. Sposito1, D. Kadrija1, A. Drudi3, D. Tregnago1, A. Avancini4, A. Gkountakos5, L. Carbognin6, A. Santo1, M. D'onofrio3, M. Lanza7, G. Tortora8, E. Bria9, M. Milella1, S. Pilotto1

Author affiliations

  • 1 Medical Oncology, University of Verona Hospital Trust, 37134 - Verona/IT
  • 2 Biostatistical Unit - Clinical Trials Center, Bio-Statistics Unit, Regina Elena National Cancer Institute, 00144 - Roma/IT
  • 3 Department Of Radiology, University of Verona Hospital Trust, 37134 - Verona/IT
  • 4 Biomedical Sciences, Department Of Medicine, University of Verona Hospital Trust, 37134 - Verona/IT
  • 5 Department Of Diagnostics And Public Health, University of Verona Hospital Trust, 37134 - Verona/IT
  • 6 Division Of Gynecologic Oncology, Department Of Woman And Child Health, Fondazione Policlinico Universitario A. Gemelli, I.R.C.C.S., Università Cattolica del Sacro Cuore, 00168 - Roma/IT
  • 7 Department Of Neurosciences, Biomedicine And Movement Sciences, University of Verona Hospital Trust, 37134 - Verona/IT
  • 8 Universita Cattolica Del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli -IRCCS Rome, 30151 - Rome/IT
  • 9 Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 - Roma/IT


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4159


Weight loss and lean body mass wasting are highly prevalent in NSCLC pts, but frequently underestimated. This study aimed to assess the prevalence of malnutrition and its correlation with outcome in A-NSCLC pts.


A-NSCLC pts treated at AOUI of Verona (2016-2018) received nutritional counselling by a qualified dietitian. Nutritional Risk Screening (NRS) 2002 was used to estimate the nutritional risk. Bilateral psoas major muscles were measured at L3 vertebrae level with routine staging-computed tomography (CT). Changes in psoas muscles were evaluated using Wilcoxon signed-rank test. Data were correlated to progression-free/overall survival (PFS/OS) and response rate (ORR) using a Cox and logistic regression model. Kaplan-Meier curves were compared with Log-Rank.


Data from 38 pts (20 males [52.6%], 18 females [47.4%]) were gathered, with a median follow-up of 21 months (range 1-197). At baseline, 18.4% were underweight, 18.4% normal weight, 34.2% overweight and 31.6% obese. The majority (65.8%) were at risk of malnutrition (NRS≥3). At multivariate analysis, stage (HR 4.99, 95% CI 1.05-27.74, p = 0.04), performance status (HR 4.99, 95% CI 1.55-16.03, p = 0.007) and NRS (HR 7.61, 95% CI 1.52-38.11, p = 0.01), were significant independent predictors for PFS. Pts with baseline NRS≤3 had significantly longer 1-year PFS (58.6% vs 16.7%, p = 0.04) and 2-year OS (90.6% vs 68.3%, p = 0.03) and a better ORR than those with NRS > 3 (66.7% vs 21.4%). A significant loss in psoas muscle mass was detected in pts treated with both immunotherapy and other therapies (p = 0.01 and p = 0.002, respectively). Of interest, in immunotherapy-treated pts (n = 16) loss in psoas muscle mass correlated with worse ORR, PFS and OS, although differences did not reach a statistical significance.


Malnutrition was common in A-NSCLC pts and associated with poor ORR, PFS and OS. Particularly, in pts treated with immunotherapy, muscle mass wasting seems to impact on efficacy outcome, suggesting a potential interaction between immunological and nutritional parameters. The introduction in clinical routine of a comprehensive nutritional profiling and monitoring is highly recommended in A-NSCLC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


E. Bria: Honoraria (self): MSD, Astra-Zeneca, Celgene, Pfizer, Helsinn, Eli-Lilly, BMS, Novartis, and Roche; Research grant / Funding (self): AIRC-IG 20583. M. Milella: Honoraria (self): Pfizer, EUSA Pharma, AstraZeneca. S. Pilotto: Honoraria (self): Astra-Zeneca, Eli-Lilly, BMS, Boehringer Ingelheim, Roche, MSD and Istituto Gentili; Research grant / Funding (self): AIRC-IG 20583. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.